Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission.
Díaz-Beyá M, Labopin M, Maertens J, Aljurf M, Passweg J, Dietrich B, Schouten H, Socié G, Schaap N, Schwerdtfeger R, Volin L, Michallet M, Polge E, Sierra J, Mohty M, Esteve J, Nagler A; Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).
Br J Haematol. 2020 Jun;189(5):920-925. doi: 10.1111/bjh.16433. Epub 2020 Feb 5.
Gilteritinib monotherapy as a transplant bridging option for high risk FLT3-mutated AML with t(6;9)(p23;q34.1);DEK-NUP214 in morphological but not cytogenetic or molecular remission following standard induction chemotherapy.
Day JW, Fox TA, Gupta R, Khwaja A, Wilson AJ, Kottaridis PD.
Leuk Res Rep. 2022 Feb 7;17:100291. doi: 10.1016/j.lrr.2022.100291. eCollection 2022.
